摘要
目的 探讨骨肉瘤组织中P 糖蛋白 (P gp)、胎盘型谷胱甘肽 S 转移酶 (GST π)和DNA拓朴酶Ⅱ (TopoⅡ )的表达及其与预后的关系。方法 应用SP法检测P gp、GST π、TopoⅡ在 80例骨肉瘤中的表达 ,并应用COX比例风险模型评估它们对预后的影响。结果 80例骨肉瘤中P gp、GST π和TopoⅡ的表达率分别为 36 2 5 %、91 2 5 %和47 5 % ,其中P gp和TopoⅡ表达与WHO新分型和预后显著相关 (P <0 0 5 )。结论 P gp、GST π、和TopoⅡ等多因素联合作用是骨肉瘤多药耐药性 (multi drugresistance,MDR)的主要作用机制 ,并且P gp和TopoⅡ可能成为评估骨肉瘤预后的有价值的指标。
Objective To study the expression of P glycoprotein (P gp), Glutathione S transferases π(GST π) and DNA topoisomerase Ⅱ (Topo Ⅱ) in osteosarcoma , and their correlation with prognosis. Method Expression of P gp, GST πand Topo Ⅱ were detected in 80 cases of osteosarcomas by SP immunohistochemical staining , and the correlation with prognosis was analyzed by a COX proportion hazard model. Results The positive rates of P gp, GST πand Topo Ⅱ were 36 25%,91 25% and 47 5% respectively in 80 cases of osteosarcomas.A significant relationship was found between P gp and Topo Ⅱ expression and WHO classification,as well as the prognosis of the patients. Conclusions Co expression of P gp, GST πand Topo Ⅱ may be the chief mechanism of multi drug resistance and an inportant panameter to predict the prognosis of patients with osteosarcoma.
出处
《诊断病理学杂志》
CSCD
2000年第1期30-32,I011,共3页
Chinese Journal of Diagnostic Pathology
